In addition, in two different xenograft mouse models harboring tumors from NRAS mutated patient‐derived melanoma cells combination therapy showed superior anti‐tumor effects compared to animals administered either monotherapy, resulting in significant survival advantages. This evidence concerns the gene NRAS and neoplasm.